TELA Bio, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8723811084
USD
1.14
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About TELA Bio, Inc. stock-summary
stock-summary
TELA Bio, Inc.
Pharmaceuticals & Biotechnology
TELA Bio Inc. is a medical technology company. The Company is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. It offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), can be used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
Company Coordinates stock-summary
Company Details
1 Great Valley Pkwy Ste 24 , MALVERN PA : 19355-1423
stock-summary
Tel: 1 484 3202930
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 20 Schemes (13.47%)

Foreign Institutions

Held by 21 Foreign Institutions (4.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Douglas Evans
Independent Chairman of the Board
Mr. Antony Koblish
President, Chief Executive Officer, Co-Founder, Director
Mr. kurt Azarbarzin
Independent Director
Mr. Vince Burgess
Independent Director
Ms. Lisa Colleran
Independent Director
Ms. Federica OBrien
Independent Director
Ms. Adele Oliva
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
20 Million
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 64 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.75

stock-summary
Return on Equity

-443.89%

stock-summary
Price to Book

6.99